Want to see TSE:ACB full AI Analyst Report?
ACB Stock Chart & Stats
C$5.54
C$0.10(2.65%)
At close: 4:00 PM EDT
C$5.54
C$0.10(2.65%)
Day’s Range― - ―
52-Week RangeC$3.59 - C$8.75
Previous CloseN/A
Volume227.23K
Average Volume (3M)334.44K
Market Cap
C$367.51M
Enterprise ValueC$117.20M
Total Cash (Recent Filing)C$149.12M
Total Debt (Recent Filing)C$22.68M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Nov 11, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding65,744,810
10 Day Avg. Volume295,769
30 Day Avg. Volume334,438
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.81
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$6.00Price Target Upside8.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.17
Revenue Forecast (FY)C$293.75M
Bulls Say, Bears Say
Bulls Say
International Medical GrowthInternational medical growth and greater revenue exposure outside Canada strengthen Aurora’s position in regulated markets. Geographic expansion can reduce reliance on Canadian demand, support scale benefits, and provide a durable platform for further growth as international markets develop.
Strong Gross MarginA 58% adjusted gross margin, supported by higher-margin international sales, indicates a favorable product and geographic mix. If sustained, this margin profile can improve operating leverage, support reinvestment, and help Aurora convert future revenue growth into stronger earnings.
Low-leverage Balance SheetNearly $150 million of liquidity with no debt provides substantial financial flexibility. This balance-sheet strength reduces refinancing pressure, supports continued investment in capacity and international expansion, and gives Aurora greater resilience while profitability and cash generation remain uneven.
Bears Say
Declining Revenue And LossesDeclining trailing revenue alongside negative operating profit and net income shows that Aurora has not yet established durable earnings power. Continued losses can constrain strategic flexibility and make the company’s longer-term growth investments more dependent on operational improvement.
Negative Free Cash FlowPersistent negative operating and free cash flow means Aurora is consuming cash rather than funding operations internally. If this continues, liquidity will gradually be pressured despite the strong balance sheet, potentially limiting investment capacity and increasing execution risk during expansion.
Canadian Reimbursement PressureThe approximately 30% reimbursement reduction is a structural regulatory headwind for Canadian medical revenue and adjusted gross profit. Lower reimbursement can compress realized pricing, weaken margins, and make international growth increasingly necessary to offset pressure in the domestic medical business.
Aurora Cannabis News
ACB FAQ
What was Aurora Cannabis’s price range in the past 12 months?
Aurora Cannabis lowest stock price was C$3.59 and its highest was C$8.75 in the past 12 months.
What is Aurora Cannabis’s market cap?
Aurora Cannabis’s market cap is C$367.51M.
When is Aurora Cannabis’s upcoming earnings report date?
Aurora Cannabis’s upcoming earnings report date is Nov 11, 2026 which is in 20 days.
How were Aurora Cannabis’s earnings last quarter?
Aurora Cannabis released its earnings results on Aug 05, 2026. The company reported -C$0.07 earnings per share for the quarter, beating the consensus estimate of -C$0.183 by C$0.113.
Is Aurora Cannabis overvalued?
According to Wall Street analysts Aurora Cannabis’s price is currently Undervalued.
Does Aurora Cannabis pay dividends?
Aurora Cannabis does not currently pay dividends.
What is Aurora Cannabis’s EPS estimate?
Aurora Cannabis’s EPS estimate is -0.07.
How many shares outstanding does Aurora Cannabis have?
Aurora Cannabis has 65,744,810 shares outstanding.
What happened to Aurora Cannabis’s price movement after its last earnings report?
Aurora Cannabis reported an EPS of -C$0.07 in its last earnings report, beating expectations of -C$0.183. Following the earnings report the stock price went up 3.836%.
Which hedge fund is a major shareholder of Aurora Cannabis?
Currently, no hedge funds are holding shares in TSE:ACB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurora Cannabis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$6.00 (8.30% Upside)
C$6.00 (8.30% Upside)
Blogger Sentiment
Bullish
TSE:ACB Sentiment 88%
Sector Average 67%
Sector Average 67%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.95%
12-Months-Change
Fundamentals
Return on Equity
-21.00%
Trailing 12-Months
Asset Growth
-28.73%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aurora Cannabis
Aurora Cannabis Inc. is a Canada-based firm specializing in the cultivation, processing, and global distribution of cannabis and its various derivative products. The company's operations encompass a broad spectrum of the cannabis industry, from facility engineering and design to genetic research, production, and the development of new products, all supported by extensive wholesale and retail networks. For medical users, Aurora offers diverse strains of dried cannabis, oils, capsules, and topical kits. Additionally, it markets a range of accessories, including vaporizers, consumable parts, herb mills (specifically for CanniMed products), grinders, and lockable vaporizer containers. The company is committed to advancing medical cannabis, with ongoing development across oral, topical, edible, and inhalable product categories. Aurora also provides key services such as patient counseling, design and construction assistance, and comprehensive analytical product testing for cannabis, alongside operating CanvasRX, a network dedicated to cannabis counseling and outreach. Its expansive brand family includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The corporate headquarters are located in Edmonton, Canada.
ACB Company Deck
ACB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: material short-term financial headwinds (notably a large year-over-year decline in adjusted EBITDA, lower adjusted net income, and negative free cash flow) driven largely by an external 30% reimbursement cut in Canadian medical. Offsetting these negatives are clear strategic strengths—17% international revenue growth to $43M, a 58% adjusted gross margin, strong cash position with no debt, an accretive EU GMP acquisition (Safari), genetics-driven production advantages (up to 40% yield improvement), and market leadership in several regulated international markets. Management frames FY2027 as a transitionary year with expected sequential improvement in Q2 and reiterated long-term targets (sustained double-digit growth and superior margins). Given the mix of significant near-term financial declines and pronounced strategic/operational positives, the overall tone is balanced.View all TSE:ACB earnings summariesACB Stock 12 Month Forecast
Average Price Target
C$6.00
▲(8.30% Upside)